Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News AstraZeneca ADR Representing 0.5 Ord Shs AZN

Consumer Cyclical Healthcare Advertising Agencies

AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex... see more

Add To Watchlist

Recent & Breaking News (NDAQ:AZN)

Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza(TM) (olaparib) In Patients with Advanced Ovarian Cancer

GlobeNewswire May 11, 2020

ENHERTU Granted Breakthrough Therapy Designation in the US for HER2-Positive Metastatic Gastric Cancer

Business Wire May 11, 2020

LYNPARZA (Olaparib) Approved in US as 1st-line Maintenance Treatment With bevacizumab For HRD-Positive Advanced Ovarian Cancer

Business Wire May 11, 2020

FARXIGA Approved in the US for the Treatment of Heart Failure in Patients With Heart Failure With Reduced Ejection Fraction

Business Wire May 6, 2020

LOKELMA US Label Updated to Include Dosing Guidance for the Treatment of Hyperkalemia in Patients With End-Stage Renal Disease on Hemodialysis

Business Wire April 27, 2020

LYNPARZA® (Olaparib) Demonstrated Overall Survival Benefit in Phase III PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer

Business Wire April 24, 2020

KOSELUGO(TM) (selumetinib) Approved In US For Pediatric Patients With Neurofibromatosis Type 1 Plexiform Neurofibromas

Business Wire April 13, 2020

RedHill Biopharma Completes Acquisition of Movantik® from AstraZeneca

GlobeNewswire April 2, 2020

BRILINTA reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial

Business Wire March 30, 2020

FARXIGA Phase III DAPA-CKD Trial Will Be Stopped Early After Overwhelming Efficacy in Patients With Chronic Kidney Disease

Business Wire March 30, 2020

IMFINZI (durvalumab) Approved in the US for Extensive-Stage Small Cell Lung Cancer

Business Wire March 30, 2020

FARXIGA reduced the incidence of heart failure worsening or cardiovascular death in a sub-analysis from landmark Phase III DAPA-HF trial

Business Wire March 28, 2020

First Patient Dosed in IPH5201 Phase I Clinical Trial in Advanced Solid Tumors

GlobeNewswire March 10, 2020

RedHill Biopharma Provides Full-Year 2019 Financial Results and Operational Highlights

GlobeNewswire March 4, 2020

RedHill Biopharma Acquires Rights to Movantik® from AstraZeneca

GlobeNewswire February 25, 2020

NeoTX Closes $45 Million Series C Financing

GlobeNewswire February 19, 2020

FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney Disease

GlobeNewswire February 11, 2020

Educational Lung Cancer Event Coming to The Villages to Raise Awareness of the State's High Rate of Lung Cancer

Business Wire January 30, 2020

BRILINTA Met Primary Endpoint in the Phase III THALES Trial in Stroke

Business Wire January 27, 2020

AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep

PR Newswire January 27, 2020